The marketing authorization for Leqembi (lecanemab), the first drug to slow the progression of Alzheimer's disease, is imminent in Korea.

According to industry sources on the 14th, the Ministry of Food and Drug Safety (MFDS) completed the safety and efficacy review of ‘Leqembi (lecanemab),’ a new drug for Alzheimer's disease that was co-developed by the Japan-based Eisai and US-based Biogen. The safety and efficacy review is the final step in Korea’s approval process, and as long as there are no serious issues during the review, the drug is granted marketing authorization.

If the drug’s official approval is announced in Korea soon, Korea will become the 4th country in the world to app